Oppenheimer Holdings, Inc. upgraded shares of TherapeuticsMD Inc (NASDAQ:TXMD) from a market perform rating to an outperform rating in a research note published on Tuesday, MarketBeat.com reports. They currently have $10.00 target price on the stock.

Other equities analysts have also recently issued research reports about the stock. CIBC reissued a market perform rating and set a $12.00 target price on shares of TherapeuticsMD in a research note on Tuesday, May 9th. Jefferies Group LLC set a $15.00 target price on shares of TherapeuticsMD and gave the company a buy rating in a research note on Wednesday, June 14th. Cantor Fitzgerald reissued an overweight rating and set a $33.00 target price on shares of TherapeuticsMD in a research note on Wednesday, May 10th. Stifel Nicolaus reissued a buy rating and set a $20.00 target price on shares of TherapeuticsMD in a research note on Wednesday, May 24th. Finally, Zacks Investment Research cut shares of TherapeuticsMD from a hold rating to a sell rating in a research note on Wednesday, May 3rd. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. TherapeuticsMD has a consensus rating of Buy and a consensus target price of $18.00.

Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 5.63 on Tuesday. The company’s 50-day moving average is $4.62 and its 200-day moving average is $5.62. The stock’s market cap is $1.15 billion. TherapeuticsMD has a 12-month low of $3.50 and a 12-month high of $8.30.

ILLEGAL ACTIVITY WARNING: “TherapeuticsMD Inc (TXMD) Upgraded at Oppenheimer Holdings, Inc.” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.watchlistnews.com/therapeuticsmd-inc-txmd-upgraded-at-oppenheimer-holdings-inc/1445035.html.

Institutional investors have recently made changes to their positions in the company. State Street Corp boosted its position in shares of TherapeuticsMD by 6.9% in the first quarter. State Street Corp now owns 3,903,491 shares of the company’s stock valued at $28,105,000 after buying an additional 253,237 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in shares of TherapeuticsMD by 94.5% in the first quarter. Oppenheimer & Co. Inc. now owns 41,466 shares of the company’s stock valued at $298,000 after buying an additional 20,148 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of TherapeuticsMD by 10.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 626,312 shares of the company’s stock valued at $4,510,000 after buying an additional 60,229 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of TherapeuticsMD by 10.1% in the first quarter. Geode Capital Management LLC now owns 1,279,601 shares of the company’s stock valued at $9,213,000 after buying an additional 117,660 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of TherapeuticsMD by 5.6% in the first quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock valued at $70,574,000 after buying an additional 515,992 shares in the last quarter.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.